Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBV-AST Cell Injection for EBV-Associated Lymphoproliferative Disorders
NCT07450391Phase 2Recruiting
- Sponsor
- Daihong Liu
- Start
- Jun 2025
- Primary completion
- Jun 2027
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of EBV-AST Cell Injection in Epstein-Barr virus associated lymphoproliferative disorder (EBV-LPD) and Epstein-Barr virus-positive diffuse large B-cell lymphoma, sponsored by Daihong Liu. Primary endpoints: Dose-Limiting Toxicities at 28 days, Incidence of Adverse Events at 12 months and 1 more. Started Jun 2025; status: recruiting.
02
Drugs
EBV-AST Cell Injection
03
Conditions
Epstein-Barr virus associated lymphoproliferative disorder (EBV-LPD)Epstein-Barr virus-positive diffuse large B-cell lymphoma
Beyond the preview
Go deeper on NCT07450391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07450391.